TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02747121

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: External inspection of health services
Description: The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External inspection of health services
Description: The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole.
Study: NCT04318587

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Allosure
Description: Blood is collected from the patient, packaged, and shipped at ambient temperature to CareDx for testing. Donor-derived cell-free DNA is measured via targeted amplification and sequencing of a set of carefully selected and validated SNPs. The AlloSure bioinformatics software calculates the percent dd-cfDNA in the sample tested and applies the QC criteria. The AlloSure results will be compared to the episodes of acute rejection diagnosed by transbronchial biopsy and BOS/CLAD diagnosed by spirometry in the subjects medical records. Transbronchial biopsies and spirometry are standard of care for lung transplant recipients.
Study: NCT01639014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F2695
Description: 75 mg OD in 2 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 capsules
Study: NCT01359514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 5 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 5 weeks
Study: NCT02117856

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1 implant placed surgically in the mandibular midline
Description: Participants receive an implant in the mandibular midline using a surgical flap procedure with local anaesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2 implants placed surgically in the mandibular canine sites
Description: Participants receive implants bilaterally in the site of the mandibular canines using a surgical flap procedure with local anaesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft reline (Coe Comfort) of the existing complete lower denture
Description: Participants receive a soft reline of the existing complete lower denture approximately 10 days after placement of the implant(s).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft reline (Coe Comfort) of the existing complete lower denture
Description: Participants receive a soft reline of the existing complete lower denture approximately 10 days after placement of the implant(s).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2.25mm ball patrix placed on 1 healed implant
Description: A 2.25mm ball patrix is screwed onto the 1 implant approximately six weeks after placement of the implant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2.25mm ball patrices placed on 2 healed implants
Description: 2.25mm ball patrices are screwed onto the 2 implants approximately six weeks after placement of the implants.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reline (Ivoclar acrylic-resin) with 1 retentive matrix in the lower denture
Description: Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 1 retentive matrix in the denture-base to retain on the implant.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reline (Ivoclar acrylic-resin) with 2 retentive matrices in the lower denture
Description: Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 2 retentive matrices in the denture-base to retain on the implants
Study: NCT02503306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVANAFIL
Description: Pharmaceutical form:tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVANAFIL
Description: Pharmaceutical form:tablets Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:tablets Route of administration: oral
Study: NCT00912054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DuoTrav APS
Description: travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalacom
Description: XALACOM® (latanoprost 50 micrograms/ml / timolol 5 mg/ml) Eye Drops, Solution
Study: NCT03275402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 131I-omburtamab
Description: Murine IgG1 monoclonal antibody radiolabeled with iodine-131
Study: NCT02399683

Intervention type: BIOLOGICAL
Intervention: Trichuris trichiura eggs
Description: Live eggs from human whipworm, Trichuris trichiura
Study: NCT01537900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: GZR 100 mg tablet by mouth q.d. for 7 days.
Study: NCT04836338

Intervention type: DEVICE
Intervention: orotracheal intubation
Description: orotracheal intubation
Study: NCT01797705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DeVilbiss AutoAdjust CPAP with revised algorithm
Description: Subjects attended a one-night polysomnogram (PSG) titration study. DeVilbiss AutoAdjust CPAP with a revised algorithm was compared to hand-scored PSG to determine whether the machine results were equivalent to hand scores. Each subject acted as their own control for assessing accuracy of sleep event analysis and prescribed CPAP pressure.
Study: NCT04059497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise condition
Description: Each participant in the intervention group can freely choose a handgrip of strength from 10 to 25kg which can be gripped with adequate grip strength. The PI will play the short video (5 minutes, www.youtube.com/watch?v=mZex2Wwy3fU) about the 10s-E for the participant, including (1) rapid grip-and-release the handgrip for at least 30 times in 10seconds in each hand, and (2) short-bout hand pushing and pulling exercises without handgrip. During the video, participants are asked to follow the 10s-E demonstrated by the medical professor. After the video, the PI will guide the participant to repeat the 10s-E for 5 times within the next 5 minutes. If participants feel pain in their hands, they can slow down the exercise. Between each exercise set, rest time for 10-20 seconds will be allowed. After practicing all these exercises, participants are asked to complete a post-intervention questionnaire

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy diet condition
Description: The control group will watch two videos on healthy diet (https://www.youtube.com/watch?v=w_u4BYV2Okc). Similar to the 10s-E condition, they will complete a post-intervention questionnaire after the two videos.
Study: NCT01176435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: Solution taken orally three times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: Solution taken orally three times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution taken orally three times a day.
Study: NCT02650726

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanin
Description: anthocyanin 320 mg daily for 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 320mg daily for 24 weeks
Study: NCT01940523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Tranexamic Acid
Description: 3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Tranexamic Acid
Description: 1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
Study: NCT03907254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Service Dog Training Program
Description: Participants will spend one hour, two times a week working with professional service dog trainers in order to shape the dog's behavior for it's future role as a service dog for service members with mobility impairments.
Study: NCT02018471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducative training
Description: The Psychological education was inspired by the technique, Systematic Desensitization (SD), a therapeutic procedure that seeks to eliminate fear and avoidance behaviour
Study: NCT03919318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Root Canal Filling Sealers
Description: Root Canal Obturation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Root Canal Filling Sealers
Description: Root Canal Obturation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Root Canal Filling Sealers
Description: Root Canal Obturation
Study: NCT00902226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Flexible-dosed (5 to 20 mg Oral Tablets Daily)
Study: NCT03122483

Intervention type: DIAGNOSTIC_TEST
Intervention: blood biomarker

Intervention type: DIAGNOSTIC_TEST
Intervention: blood biomarker
Study: NCT01049984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: 1mg tablet daily for 18 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet daily for 18 weeks
Study: NCT03194854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fun For Wellness (FFW)
Description: FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
Study: NCT01271036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formula PD-F-7716
Description: Apply a dime-size amount on each application site as instructed during the 1-week study period
Study: NCT02512861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 0.25% Bupivacaine at 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5% Bupivacaine at 0.5 ml/kg up to a maximum of 25ml of 0.5% Bupivacaine for patients \> 50 kgs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients \> 50 kgs
Study: NCT03730311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida
Description: elsulfavirine, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida
Description: elsulfavirine, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida
Description: elsulfavirine, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study: NCT02254681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose radiotherapy
Description: Whole liver and portal lymph node basin low dose radiotherapy
Study: NCT04237129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gan & Lee Insulin Aspart
Description: All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area.
Study: NCT02685007

Intervention type: OTHER
Intervention: Tachosil
Description: TachoSil is a collagen matrix that is coated with human fibrinogen and human thrombin.
Study: NCT03391583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants in the education arm of the study will be provided with three PowerPoint presentations. Material for these slides has been adapted from material developed by the Ontario Neurotrauma Foundation. Topics to be addressed will surround post-traumatic headache and will include information regarding common symptoms, timeline for improvement, red- flags and when to seek medical attention
Study: NCT01930877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine iv bolus followed by infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Normal saline bolus followed by infusion
Study: NCT04486079

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricia PreOp
Description: A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
Study: NCT03891498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MgSO4
Description: The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
Study: NCT01486511

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Hepatectomy including both minor and major.

Intervention type: RADIATION
Intervention: Computed Tomography
Description: Computed Tomography +/- pulmonary angiography
Study: NCT02987322

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: honey
Description: Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months
Study: NCT01829828

Intervention type: BEHAVIORAL
Intervention: No intervention
Description: This is an observational study with no investigational drug administered.
Study: NCT00996359

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Irradiated haploidentical allogeneic lymphocytes
Description: Partially HLA-matched irradiated donor lymphocytes will be infused after total body irradiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: 100 cGy TBI
Study: NCT03321656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: 0.1-0.2 mg/kg/day orally divided into two doses every 12 hours orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus XR
Description: 0.07-0.14 mg/kg/day every morning orally
Study: NCT02846597

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained lung inflation in preterms (SLI).
Description: Providing a positive pulmonary ventilation with an opening lung pressure for the first breath of preterm infant for a sustained period of time

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained lung inflation in preterms (SLI).
Description: Providing a positive pulmonary ventilation with an opening lung pressure for the first breath of preterm infant for a sustained period of time

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained lung inflation in preterms (SLI).
Description: Providing a positive pulmonary ventilation with an opening lung pressure for the first breath of preterm infant for a sustained period of time

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained lung inflation in preterms (SLI).
Description: Providing a positive pulmonary ventilation with an opening lung pressure for the first breath of preterm infant for a sustained period of time
Study: NCT02844348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis session
Study: NCT03952728

Intervention type: BEHAVIORAL
Intervention: Intensive lifestyle intervention
Description: Lifestyle intervention focused on weight loss through diet and physical activity

Intervention type: BEHAVIORAL
Intervention: Diabetes support and education
Description: Behavioral intervention focused on diabetes support and education
Study: NCT06031870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal pessary
Description: In the pessary group, all patients received a cube pessary, which was individually adapted to each patient. These pessaries exist in sizes 0 (25 mm edge length) to 9 (75 mm edge length). Patients were instructed by a physician or a trained nurse on how to autonomously manage the pessary, including daily changing and cleaning. After one week of treatment, all patients had an office visit to check if fitting was correct and if autonomous handling of the pessary was feasible. Treatment duration was 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care consisted of a pelvic floor group exercise course led by a midwife, a physiotherapist, or an osteopath. Courses were in general once a week for a minimum of seven to a maximum of twelve weeks. The course was chosen by the patient, and the study team had no influence on the choice.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: Twelve pelvic floor physiotherapy sessions were prescribed by the study physician. Pelvic floor physiotherapy was performed in individual courses by trained physiotherapists. The patient was free to choose the physiotherapist and the study team had no influence on the choice.
Study: NCT03807700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Denture Adhesive
Description: In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
Study: NCT04237129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gan & Lee Insulin Aspart
Description: All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gan & Lee Insulin Aspart
Description: All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area.
Study: NCT02407132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted DSME
Description: Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard DSME
Description: Active Comparator: Standard DSME Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
Study: NCT01264354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine 30mg
Description: Clevudine 30mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine 20mg+Adefovir dipivoxil 10mg
Description: Clevudine 20mg+ Adefovir 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine 20mg
Description: Clevudine 20mg
Study: NCT03294421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined access tympanomastoidectomy
Description: Trans canal surgery with the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation allowing better visualization and removal of the cholesteatoma before mastoid debridement. In this surgery, mastoid debridement is conducted only if there was no full endoscopic removal of the cholesteatoma. The other procedures of this type of surgery are similar to the standard tympanomastoidectomy technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard closed tympanomastoidectomy
Description: 1. Supine position and general anesthesia with orotracheal intubation~2. Antisepsis and placing of sterile fields~3. Local anesthesia of the external auditory canal with lidocaine 2% and adrenaline 1:100. 000 UI~4. Retroauricular incision~5. Removal of the temporal muscle fascia~6. Elevation of the surgical flap of the tympanic meatus~7. Visualization and exploration of the cholesteatoma~8. Exploration of the ossicular chain~9. Mastoid debridement~10. Conservation of the upper posterior wall of the auditory conduct~11. Removal of the cholesteatoma~12. Tympanoplasty with the temporal fascia~13. Retroauricular suture with vycril 3.0 and mononylon 4.0